Any current/future new fundraising through debt or equity?

No new expansion CAPEX is planned until business performance improves; current CAPEX (around Rs. 390 crore for benzene derivatives) to be completed within FY24. All future cash flows post-CAPEX are planned to be used primarily for debt repayment. Current gross debt stands at around Rs. 875 crore (Rs. 550 crore term debt + Rs. 325 crore working capital debt), with net debt about Rs. 800 crore. Debt expected to be around Rs. 350 crore term debt by FY26 and working capital to remain at Rs. 300-350 crore. Some non-core asset sale (land, factory in Ahmedabad valued at approx. Rs. 100 crore) is plan

Any current/future capex/capital investment/strategic investment?

The company has completed a major CAPEX for benzene derivatives of around Rs. 390 crores within the current year; most payments (about Rs. 30 crores) are pending. No further CAPEX or expansion is planned for the next two years until business performance improves. All future cash flows are expected to be utilized towards debt repayment rather than new capital investments. The company is focusing on stabilizing and optimizing the newly set-up benzene derivatives plant with an installed capacity of 63,000 tons per annum, expecting significant revenue (~Rs. 320 crores) and better margins (12

Future growth expectations in sales/revenue/volumes?

The company expects additional revenue of around Rs. 320 crores from the new benzene derivatives plant at optimum utilization by next year onwards. Benzene derivatives segment aims to contribute roughly 25%-30% of overall topline with EBITDA margins of 12%-15%. Capacity utilization for benzene derivatives is expected to ramp up to 50%-70% within 3-4 months and reach over 80% in subsequent months. No major CAPEX planned for the next two years; generated cash flows will focus on debt repayment. Dye intermediate revenue showed a 19% year-on-year growth in 9M FY24, indicating volume growth

Future growth expectations in earnings/operating earnings/profits/EPS?

Bodal Chemicals expects revenue growth from the new benzene derivatives business, anticipating Rs. 320 crore additional revenue at optimum utilization with 12%-15% EBITDA margins. Current EBITDA margins of 7%-8% are expected to improve to around 10%-13% over the next few years with new business addition and cost rationalization. The company aims to gradually close smaller, less profitable units to reduce fixed overheads and improve margins. No major CAPEX is planned until business performance improves; free cash flows will be directed towards debt reduction. By FY26, term debt is expec

Bodal Chemicals LtdQ3 FY24Chemicals & Petrochemicals

Bodal Chemicals Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹190P/E: 37.0Market Cap: ₹2.5K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

N/A

Capex

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects additional revenue of around Rs. 320 crores from the new benzene derivatives plant at optimum utilization by next year onwards.
Benzene derivatives segment aims to contribute roughly 25%-30% of overall topline with EBITDA margins of 12%-15%.
Capacity utilization for benzene derivatives is expected to ramp up to 50%-70% within 3-4 months and reach over 80% in subsequent months.
No major CAPEX planned for the next two years; generated cash flows will focus on debt repayment.
Dye intermediate revenue showed a 19% year-on-year growth in 9M FY24, indicating volume growth potential.
Caustic soda volumes grew by 25% in 9M FY24 despite price pressure; demand expected to remain healthy from FMCG, textile, and paper sectors.
Overall volumes and demand are gradually improving post multiple global headwinds, with December-January numbers better than previous quarters.

Margin guidance

Category 1

Bodal Chemicals expects revenue growth from the new benzene derivatives business, anticipating Rs. 320 crore additional revenue at optimum utilization with 12%-15% EBITDA margins.
Current EBITDA margins of 7%-8% are expected to improve to around 10%-13% over the next few years with new business addition and cost rationalization.
The company aims to gradually close smaller, less profitable units to reduce fixed overheads and improve margins.
No major CAPEX is planned until business performance improves; free cash flows will be directed towards debt reduction.
By FY26, term debt is expected to be around Rs. 350 crore, and working capital to remain at Rs. 300-350 crore levels, reflecting improved financial health.
Overall, Bodal targets to elevate EBITDA margins to around 12%-13%, up from recent lows of 7%-8%, with steady long-term profitability improvement.

See what Bodal Chemicals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

No new expansion CAPEX is planned until business performance improves; current CAPEX (around Rs. 390 crore for benzene derivatives) to be completed within FY24.
All future cash flows post-CAPEX are planned to be used primarily for debt repayment.
Current gross debt stands at around Rs. 875 crore (Rs. 550 crore term debt + Rs. 325 crore working capital debt), with net debt about Rs. 800 crore.
Debt expected to be around Rs. 350 crore term debt by FY26 and working capital to remain at Rs. 300-350 crore.
Some non-core asset sale (land, factory in Ahmedabad valued at approx. Rs. 100 crore) is planned to reduce debt over the next 1 to 1.5 years.
Weighted average cost of debt is about 8.5%, with possible incremental increases of 0.5% due to rating changes.
No mention of equity fundraising during the call.

Order book

The transcript provided does not specifically mention details about the current or expected order book or pending orders for Bodal Chemicals Limited. However, some relevant insights related to business and demand include: - Company is witnessing a gradual pickup in volumes but demand is not aggressive yet. - International demand and volumes have normalized after a de-stocking phase of several quarters. - Benzene derivatives business is expected to add additional revenue of around Rs. 320-330 crores at optimum utilization. - The company is focusing on debt repayment and not planning any immediate CAPEX until business performance improves. - No explicit commentary on current order book size or pending orders was given during the call. Hence, no concrete figure or direct reference to the order book or pending orders is provided in the transcript.

See what Bodal Chemicals Ltd management said on order book — free account, 30 seconds.

Capex plans

The company has completed a major CAPEX for benzene derivatives of around Rs. 390 crores within the current year; most payments (about Rs. 30 crores) are pending.
No further CAPEX or expansion is planned for the next two years until business performance improves.
All future cash flows are expected to be utilized towards debt repayment rather than new capital investments.
The company is focusing on stabilizing and optimizing the newly set-up benzene derivatives plant with an installed capacity of 63,000 tons per annum, expecting significant revenue (~Rs. 320 crores) and better margins (12%-15%) from next year onwards.
Strategic actions include shutting down smaller, less profitable older units to save fixed overheads and improve margins.
The company is also evaluating non-core asset sales (including land and factory in Ahmedabad valued around Rs. 100 crores) to reduce debt.

Track Bodal Chemicals Ltd — get its next earnings analysis in your feed

How does Bodal Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisBodal Chemicals Ltd

Rev 3Mar 1

See where Bodal Chemicals Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Bodal Chemicals Ltd rank in Chemicals & Petrochemicals?

Compare Bodal Chemicals Ltd against every Chemicals & Petrochemicals company (Q3 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Bodal Chemicals Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →